Bhushan Munjal

Dr. Bhushan Munjal

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
RJRayanta P. Joshi
Rayanta P. Joshi
GNGeeta Negi
Geeta Negi
AKAshutosh Kumar
Ashutosh Kumar
YPYogesh B. Pawar
Yogesh B. Pawar
BMBhushan Munjal
Bhushan Munjal
SSShyam S. Sharma
Shyam S. Sharma

1 July 2020 in Journal of Controlled Release
Verified
Journal Article
Closed access
ATAlpana A. Thorat
Alpana A. Thorat
BMBhushan Munjal
Bhushan Munjal
TGTodd W. Geders
Todd W. Geders
RSRaj Suryanarayanan
Raj Suryanarayanan

27 August 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
STSeema Thakral
Seema Thakral
JSJayesh Sonje
Jayesh Sonje
BMBhushan Munjal
Bhushan Munjal
BBBakul Bhatnagar
Bakul Bhatnagar
RSRaj Suryanarayanan
Raj Suryanarayanan

1 October 2012 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
YPYogesh B. Pawar
Yogesh B. Pawar
HPHitesh Purohit
Hitesh Purohit
GVGuru Raghavendra Valicherla
Guru Raghavendra Valicherla
BMBhushan Munjal
Bhushan Munjal
SLShantanu V. Lale
Shantanu V. Lale
ABArvind Kumar Bansal
Arvind Kumar Bansal

9 October 2012 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YPYogesh B. Pawar
Yogesh B. Pawar
BMBhushan Munjal
Bhushan Munjal
SASaurabh Arora
Saurabh Arora
MKManoj Karwa
Manoj Karwa
GKGunjan Kohli
Gunjan Kohli
Arvind BansalArvind Bansal
Arvind Bansal
Numerous publications have reported the significant pharmacodynamic activity of Curcumin (CRM) despite low or undetectable levels in plasma. The objective of the present study was to perform a detailed pharmacokinetic evaluation of CRM after the oral administration of a highly bioavailable lipidic formulation of CRM (CRM-LF) in human subjects. Cmax, Tmax and AUC0–¥ were found to be 183.35 ± 37.54 ng/mL, 0.60 ± 0.05 h and 321.12 ± 25.55 ng/mL respectively, at a dose of 750 mg. The plasma profile clearly showed three distinct phases, viz., absorption, distribution and elimination. A close evaluation of the primary pharmacokinetic parameters provided valuable insight into the behavior of the CRM after absorption by CRM-LF. CRM-LF showed a lag time (Tlag) of 0.18 h (around 12 min). Pharmacokinetic modeling revealed that CRM-LF followed a two-compartment model with first order absorption, lag time and first order elimination. A high absorption rate constant (K01, 4.51/h) signifies that CRM-LF ensured rapid absorption of the CRM into the central compartment. This was followed by the distribution of CRM from the central to peripheral compartment (K12, 2.69/h). The rate of CRM transfer from the peripheral to central compartment (K21, 0.15/h) was slow. This encourages higher tissue levels of CRM as compared with plasma levels. The study provides an explanation of the therapeutic efficacy of CRM, despite very low/undetectable levels in the plasma.

11 May 2011 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
BMBhushan Munjal
Bhushan Munjal
YPYogesh Bapurao Pawar
Yogesh Bapurao Pawar
SPSarsvatkumar Babulal Patel
Sarsvatkumar Babulal Patel
Arvind BansalArvind Bansal
Arvind Bansal